Insider Buying: Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Purchases 56,054 Shares of Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) Director Robert W. Duggan acquired 56,054 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The shares were purchased at an average price of $17.35 per share, with a total value of $972,536.90. Following the completion of the acquisition, the director now owns 42,228,057 shares of the company's stock, valued at $732,656,788.95. This represents a 0.13 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pulse Biosciences Trading Up 3.0 %

Pulse Biosciences stock traded up $0.51 during mid-day trading on Friday, hitting $17.65. 314,720 shares of the company's stock traded hands, compared to its average volume of 200,806. The firm has a 50 day simple moving average of $17.68 and a two-hundred day simple moving average of $16.40. Pulse Biosciences, Inc. has a fifty-two week low of $6.59 and a fifty-two week high of $22.69.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the previous year, the company earned ($0.19) EPS.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research note on Thursday.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PLSE. Franklin Resources Inc. acquired a new position in Pulse Biosciences in the 3rd quarter worth about $378,000. Barclays PLC increased its holdings in Pulse Biosciences by 361.4% in the third quarter. Barclays PLC now owns 30,306 shares of the company's stock valued at $530,000 after purchasing an additional 23,738 shares during the period. Geode Capital Management LLC raised its position in shares of Pulse Biosciences by 7.8% during the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company's stock worth $8,020,000 after acquiring an additional 33,200 shares during the last quarter. State Street Corp raised its holdings in Pulse Biosciences by 17.8% during the 3rd quarter. State Street Corp now owns 461,333 shares of the company's stock worth $8,092,000 after purchasing an additional 69,696 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Pulse Biosciences in the third quarter valued at $588,000. Institutional investors and hedge funds own 76.95% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.